12:00 AM
 | 
Jan 10, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 1/7cls
Acorda Therapeutics Inc. (NASDAQ:ACOR) Leerink Joshua Schimmer Upgrade Market outperform
(from market perform) 2% $27.67
Schimmer upgraded based on his monthly patient modeling for Acorda's Ampyra dalfampridine to improve walking ability in multiple sclerosis patients. He expects prescriptions, which had flattened over the past few months, to start to grow again this month and to continue growing through...

Read the full 575 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >